Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia Alten

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Hemasphere|February 26, 2026
Intra-subtype heterogeneity shapes treatment response in <i>KMT2A</i>-rearranged ALL across all age groupsAlina M Hartmann, Lorenz Bastian, Malwine J Barz, et al.
Blood Advances|October 25, 2019
Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targetsJessica I Hoell, Sebastian Ginzel, Michaela Kuhlen, et al.
Haematologica|February 6, 2025
Update on long-term outcomes of a cohort of patients with <i>TCF3::HLF</i>-positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantationAida Zeckanovic, Brice Mouttet, Luciana Vinti, et al.
Blood|January 12, 2024
CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatmentBarbara Buldini, Elena Varotto, Margarita Maurer-Granofszky, et al.
Blood|March 22, 2024
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosisLennart Lenk, Irène Baccelli, Anna Laqua, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Hemasphere|February 26, 2026
Intra-subtype heterogeneity shapes treatment response in <i>KMT2A</i>-rearranged ALL across all age groupsAlina M Hartmann, Lorenz Bastian, Malwine J Barz, et al.
Blood Advances|October 25, 2019
Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targetsJessica I Hoell, Sebastian Ginzel, Michaela Kuhlen, et al.
Haematologica|February 6, 2025
Update on long-term outcomes of a cohort of patients with <i>TCF3::HLF</i>-positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantationAida Zeckanovic, Brice Mouttet, Luciana Vinti, et al.
Blood|January 12, 2024
CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatmentBarbara Buldini, Elena Varotto, Margarita Maurer-Granofszky, et al.
Blood|March 22, 2024
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosisLennart Lenk, Irène Baccelli, Anna Laqua, et al.
Pageof 4